

December 20, 2023

Patented Medicine Prices Review Board (PMPRB) 333 Laurier Avenue West, Suite 1400 Ottawa ON, K1P 1C1

Subject: PMPRB Scoping Paper consultation (2023)

Dear PMPRB Board Members,

The Canadian Organization for Rare Disorders (CORD) is the national alliance of over 100 rare disease patient organizations and representing approximately 3 million Canadians affected by rare diseases.

On behalf of our patients and families, I would you like to commend you for taking a refreshed perspective on the guidelines development process. We are especially heartened that the PMPRB appears to be returning to its core mandate, which hopefully will help turn the page on what has been a very traumatic chapter for CORD and the rare disease community.

Based on the media hype and disinformation campaigns, one would be excused in imagining that the hospitals and pharmacies are overflowing with expensive rare disease therapies. Nothing could be further from the truth, with less than 5% of rare diseases having an approved treatment and many of these delayed in their entry to Canada, and some, not at all.

However, our community wants to move forward constructively and not dwell on the collective stress and apprehension caused by the proposed changes over the past seven years. On behalf of Canadian rare disease families, of which my family is one, I urge you to keep us forefront in your minds as you deliberate on your new guidelines. Here are examples of why appropriate pricing regulations are essential to rare disease families.

- A young woman diagnosed with fibrodysplasia ossificans progressiva (FOP), a rare
 musculoskeletal condition whereby, after birth and progressively through life, muscles and
 tendons are gradually transformed into bone (similar to the condition affecting Celine
 Dion). A treatment developed in Quebec more than eight years ago has now been
 approved by Health Canada and recommended by CADTH. It is awaiting consideration for
 pricing negotiations but the process could be further delayed by the fact that drug was just
 approved by the FDA this past August so there are limited international benchmarks.
- A 10-year-old boy with Neurofibromatosis type 1 (NF1), has undergone numerous surgeries to remove tumours throughout his body, and now has new growths near his spine. An oral therapy that has been shown to shrink the tumours, thus reducing pain and avoiding surgery, was approved in 2020 and 2021 in the USA and EU, respectively. Submission to Health Canada was delayed several years until pricing and reimbursement had been secured elsewhere. Several children could have avoided surgery with more timely access.
- A 21-year-old student with homozygous familial hypercholesterolemia (HOFH), a genetic condition characterized by very high LDL-C levels, travels four hours every two weeks to



receive plasma transfusions. However, these are not very effective and she has experienced several cardiovascular events. A new drug infused monthly is effective in reducing LDL-C by nearly 50%. Its submission in Canada was delayed for about two years until after EU and USA had negotiated pricing and reimbursement. She suffered her last attack during that delay.

These are only a few examples of the many serious impacts on rare disease patients, with many companies choosing to delay or even forego bringing life-altering and life-saving therapies to Canada, citing the unreasonable, un-negotiable and unprecedented changes in how PMPRB operates, which would have put our pricing ceilings far below other OECD countries. Rare disease patients are still suffering from delayed and no entry of therapies during these past years, many of which are the first for that condition.

To illustrate these challenges, we have updated and attached a list of medicines approved by the United States Food & Drug Agency versus submissions to Health Canada, finding that since the first formal *Patented Medicines Regulations* changes were published on August 22, 2019, only 102 out of the 197 medicines already approved in the US have even been submitted for review by Health Canada as of December 6, 2023. This means that Canadians have access to only about half of the medicines available just south of the border, including treatments for many cancers, Alzheimer's disease, diabetes, and other serious diseases. These are deliberate choices made by companies driven in part by the uncertainty surrounding compliant pricing and the potential impacts on pricing in other markets.

As patients, we wholeheartedly endorse the essence of the PMPRB's mandate, which is to prevent excessive prices for patented medicines and report on pricing and research trends in Canada. Sadly, the previous reforms strayed far from this objective. The focus on driving prices down without adequately considering the impact on patient access contradicts the foundation upon which this organization was built.

In light of these issues, CORD takes some comfort that the PMPRB has begun to engage in more meaningful consultations, and this starts with considering the real impact of pricing policies on patients. This can only be achieved through a thorough review of operational changes with practical case studies. Collaboration with patients, clinicians, payers, and stakeholders is crucial in formulating pricing guidelines that serve everyone's interests.

A measure of success or failure for the PMPRB needs to be an understanding of how its regulatory role – reviewing prices for potential excessiveness – is either enabling or obstructing the opportunity to access rare disease research and medicines in Canada.

As the PMPRB begins to reflect on its guidelines approach, we encourage you to consider the following key questions:

- 1. How will the PMPRB changes enable the implementation of Canada's rare disease drug strategy?
- 2. How would updated price ceilings affect the capacity for health systems and payers to negotiate dynamic agreements that provide access to medicines and the full range of care required for precision medicines, including cell and gene therapies? In Canada, our payers are getting creative and negotiating managed access programs and outcomesbased agreements. How can the PMPRB support these efforts, which are the hallmark of access for rare diseases in other countries and, increasingly, in Canada?

151 Bloor Street West, Suite 600, Toronto, M5S 1S4 Phone: 416-969-7435 Fax 416-969-7420 web: raredisorders.ca



3. How do you plan to benchmark or monitor for excessive prices when a medicine is only available in a jurisdiction that isn't within the PMPRB11, for example, the US, where most medicines are made available first?

CORD has been active in the development and implementation of rare disease strategies and we are ready to bring our collective ingenuity to bear on these and other questions as you move forward. We would welcome the opportunity to take part in any guidelines steering groups, as we have done in the past.

Thank you for the opportunity to provide input.

Sincerely,

Durhane Wong-Rieger, PhD

Durling ?

President & CEO

durhane@raredisorders.ca

Encl.



Drug Name	Active Ingredient	FDA Approval Date	Submitted to HC?	HC Submission/Approval Notes	Treatment / Use
Drug Name	Active ingredient	FUA Approval Date	Submitted to HC:	HC Submission/Approval Notes	Treatment / Use To treat adults with progressing desmoid tu
Ogsiveo	nirogacestat	27-Nov-23	No		who require systemic treatment
		45 Nov. 22	V		To treat breast cancer that meets certain di
Truqap Ryzneuta	capivasertib efbemalenograstim alfa-vuxw	16-Nov-23 16-Nov-23	Yes No	New active substance	criteria To treat neutropenia
.,	Electrical Broad and Talk	20 1101 22			Bo treat ROS1-positive non-small cell lung
Augtyro	repotrectinib	15-Nov-23	No		cancer
					To reduce the incidence of catheter-related
					bloodstream infections in adults with kidne failure receiving chronic hemodialysis throu
Defencath	taurolidine, heparin	15-Nov-23	No		central venous catheter
Fruzaqla	fruquintinib	08-Nov-23	No		To treat refractory, metastatic colorectal ca
					To treat recurrent or metastatic nasophary
Loqtorzi	toripalimab-tpzi	27-Oct-23	No		carcinoma when used together with or follo other therapies
Omvoh	mirikizumab-mrkz	26-Oct-23	No		To treat ulcerative colitis
■gamree	vamorolone	26-Oct-23	No		To treat Duchenne muscular dystrophy
					To treat moderate to severe plaque psorias
					adults who are candidates for systemic ther
Bimzelx	bimekizumab		Yes	Issued NOC	or phototherapy
					To treat generalized myasthenia gravis in ad who are anti-acetylcholine receptor (AChR)
Zilbrysq	zilucoplan	17-Oct-23	Yes	New active substance	antibody positive
		2, 00-23			To treat moderately to severely active ulcer
B elsipity	etrasimod	12-Oct-23	Yes	New active substance	colitis in adults
					To lower urinary oxalate levels in patients 9
Rivfloza	nedosiran	29-Sep-23	No		and older with primary hyperoxaluria type : relatively preserved kidney function
Pombiliti	cipaglucosidase alfa-atga	28-Sep-23	No		To treat late-onset Pompe disease
Exxua	gepirone	22-Sep-23			To treat major depressive disorder
					To treat intermediate or high-risk myelofibr
Ojjaara	momelotinib	15-Sep-23	No		in adults with anemia
					To use with filgrastim (G-CSF) to mobilize
					hematopoietic stem cells to the peripheral b
					for collection and subsequent autologous transplantation in patients with multiple
Aphexda	motixafortide	08-Sep-23	No		myeloma
					To treat patients 1 year old and older with 0
					deficient protein-losing enteropathy (PLE), a
■eopoz	pozelimab-bbfg	18-Aug-23	No		known as CHAPLE disease
					To reduce the volume of new heterotopic
					ossification in adults and pediatric patients
					8 years and older for females and 10 years
Cohonor	paleyaretene	16 Aug 22	Voc	Issued NOC in Jan. 2022	older for males) with fibrodysplasia ossifica progressiva
Sohonos	palovarotene	16-Aug-23	Yes	Issued NOC III Jan. 2022	progressive
				New active substance; Being reviewed	To treat adults with relapsed or refractory
				under the Notice of Compliance with	multiple myeloma who have received at leas
Elrexfio	elranatamab-bcmm	14-Aug-23	Yes	Conditions Guidance	four prior lines of therapy
					To treat adults with relapsed or refractory
Balvey	talquetamab-tgvs	09-Aug-23	Yes	New active substance	multiple myeloma who have received at lea four prior therapies
and the same of	raidacramas-r843	US AUG ES	163	New delive Substance	To treat geographic atrophy secondary to a
E tervay	avacincaptad pegol	04-Aug-23	No		related macular degeneration
Zurzuvae	zuranolone	04-Aug-23	No		To treat postpartum depression
Xdemvy	lotilaner	25-Jul-23	No		To treat Demodex blepharitis
					To use as part of a treatment regimen for n
					diagnosed acute myeloid leukemia that mee
Vanflyta	quizartinib	20-Jul-23	No		certain criteria To prevent respiratory syncytial virus (RSV)
Beyfortus	nirsevimab-alip		Yes	Issued NOC in Apr. 2023	respiratory tract disease
,,,,,,,,,,					Bo treat growth failure due to inadequate
Ngenla	somatrogon-ghla	27-Jun-23	Yes	Issued NOC in Oct. 2021	secretion of endogenous growth hormone
					To treat generalized myasthenia gravis in ac
Durtiese	rozznoliviz		No.		who are anti-acetylcholine receptor- or anti-
Rystiggo Eitfulo	rozanolixizumab-noli ritlecitinib	26-Jun-23 23-Jun-23	No Yes	New active substance, Feb. 2023	muscle-specific tyrosine kinase antibody-po To treat severely patchy hair loss
Ettulo	Mueciamo	23-Juli-23	Tes	New active substance, Feb. 2025	To treat severely patchy half loss
					To treat diffuse large B-cell lymphoma, not
					otherwise specified, or large B-cell lymphon
					arising from follicular lymphoma after two
Eolumvi	glofitamab-gxbm	15-Jun-23	Yes	Issued NOCc in Mar. 2023	more lines of systemic therapy
Inpefa	sotagliflozin	26-May-23	No		To treat heart failure
					To treat mild-to-moderate COVID-19 in adu
Baxlovid	nirmatrelvir, ritonavir	25-May-23	Yes	Issued NOC in Jan. 2022	high risk for progression to severe COVID-19 in adu
BUNDAN	, INCHES	23-Iviay-23	,63		
					To treat hospital-acquired bacterial pneumo
					and ventilator-associated bacterial pneumo
					caused by susceptible isolates of Acinetoba
Xacduro	sulbactam, durlobactam	23-May-23	No		baumannii-calcoaceticus complex
				Name and the substance	To treat relapsed or refractory diffuse large
				New active substance; Being reviewed	lymphoma (not otherwise specified) and hig
	epcoritamab-bysp	10.1434 33	Vac	under the Notice of Compliance with Conditions Guidance	grade B-cell lymphoma after two or more lin systemic therapy
Enkink	lehcouraman-nAzb	19-May-23	Yes	Conditions Guidance	
Epkinly					To treat moderate to severe hot flashes caus



Elfabrio	pegunigalsidase alfa-iwxj	09-May-23	No		To treat confirmed Fabry disease
0-11-		05.403			To treat amyotrophic lateral sclerosis in
Qalsody	tofersen	25-Apr-23	No		adults who have a SOD1 gene mutation To treat activated phosphoinositide 3-kinase
Joenja	leniolisib	24-Mar-23	Yes	New active substance	delta syndrome
_					
Rezzayo	rezafungin	22-Mar-23	No		To treat candidemia and invasive candidiasis To treat metastatic or recurrent locally
Z ynyz	retifanlimab-dlwr	22-Mar-23	No		advanced Merkel cell carcinoma
Daybue	trofinetide	10-Mar-23	No		To treat Rett syndrome
Zavzpret	zavegepant	09-Mar-23	No		To treat migraine
Skyclarys	omaveloxolone	28-Feb-23	No		To treat Friedrich's ataxia To reduce proteinuria in adults with primary
					immunoglobulin A nephropathy at risk of
Eilspari	sparsentan	17-Feb-23	No		rapid disease progression
Lamzede		16-Feb-23	No		To treat non-central nervous system
Lamzeue	velmanase alfa-tycv	10-reb-23	NO	Part of 'aligned review' with a	manifestations of alpha-mannosidosis To treat anemia caused by chronic kidney
				health technology assessment	disease for adults on dialysis for at least fou
Jesduvroq®	daprodustat	01-Feb-23	Yes	organization	months
					To treat estrogen receptor-positive, human
					epidermal growth factor receptor 2-negative
					ESR1-mutated, advanced or metastatic brea
		07.103			cancer with disease progression following at
Orserdu	elacestrant	27-Jan-23	No	 	least one line of endocrine therapy Bio treat relapsed or refractory mantle cell
					lymphoma in adults who have had at least
					two lines of systemic therapy, including a B1
Eaypirca	pirtobrutinib	27-Jan-23	No		inhibitor The improve glycemic control in adults with
					Ho improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to die
Brenzavvy	bexagliflozin		No		and exercise
Begembi	lecanemab-irmb	06-Jan-23	Yes	New active substance	Bo treat Alzheimer's disease
Briumvi	ublituximab-xiiy	28-Dec-22	No		To treat relapsing forms of multiple sclerosis
Briumvi	ubilituximab-xily	28-Det-22	NO		To treat adults with relapsed or refractory
					follicular lymphoma, a type of non-Hodgkin
Lunsumio	mosunetuzumab-axgb	22-Dec-22	No		lymphoma
					Bo treat adults with HIV whose HIV
					infections cannot be successfully treated wit
					other available treatments due to resistance
Sunlenca	E enacapavir	12-Dec-22	Yes	NOC in Dec. 2022	intolerance, or safety considerations
					To treat KRAS G12C-mutated locally advanced or metastatic non-small cell lung
					cancer in adults who have received at least
Erazati	adagrasib	12-Dec-22	No		one prior systemic therapy
					To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible
Bezlidhia	Blutasidenib	01-Dec-22	No		isocitrate dehydrogenase-1 (IDH1) mutation
E zield	Replizumab-mzwv	18-Nov-22	No		To delay the onset of stage 3 type 1 diabetes
					To treat patients with recurrent ovarian
Bahere	mirvetuximab soravtansine-gynx	14-Nov-22	No		cancer that is resistant to platinum therapy
				Being reviewed under the Notice of Compliance with Conditions	To treat relapsed or refractory multiple myeloma among adults who have received a
Tecvayli	teclistamab-cqyv	25-Oct-22	Yes	Guidance	least four specific lines of therapy
					To treat unresectable hepatocellular
Imjudo	tremelimumab	21-Oct-22	Yes	Submitted May 2022	carcinoma
					To treat intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor
Bytgobi	futibatinib	30-Sep-22	No		(FGFR2) gene fusions or other
77-6		22 och 22			, and good and the
Relyvrio	sodium phenylbutyrate/taurursodio	29-Sep-22	Yes	NOC in June 2022	To treat amyotrophic lateral sclerosis (ALS)
					To improve kidney function in adults with hepatorenal syndrome with rapid reduction
Terlivaz	terlipressin	14-Sep-22	No		in kidney function
	·				
					To decrease the incidence of infection in
					patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drug
					associated with clinically significant incidence
Rolvedon	eflapegrastim	09-Sep-22	No		of febrile neutropenia
Catadate	dougrapacitie-ib	00.0 00	V	Now active cubetones	To treat moderate to course the course
Sotyktu	deucravacitinib	09-Sep-22	Yes	New active substance	To treat moderate-to-severe plaque psoriasi To treat moderate-to-severe glabellar lines
					associated with corrugator and/or procerus
Daxxify	daxibotulinumtoixnA-lanm	07-Sep-22	No		muscle activity
Consider	limat star	04.0 00	V	Being reviewed under the Priority	To transfer de la contraction
Spevigo	spesolimab-sbzo	01-Sep-22	Yes	Review Policy Being reviewed under the Priority	To treat generalized pustular psoriasis flares
Xenpozyme	Olipudase alfa	31-Aug-22	Yes	Review Policy	To treat Acid Sphingomyelinase Deficiency
					To treat polyneuropathy of hereditary
Amvuttra	vutrisiran	13-Jun-22	Yes	New active substance	To treat plaque progracis
Vtama	tapinarof	23-May-22	Yes	New active substance	To treat plaque psoriasis
Mounjaro	tirzepatide	13-May-22	Yes	Submitted February 2022	To improve blood sugar control in diabetes



	vonoprazan, amoxicillin, and				
Voquezna	clarithromycin	03-May-22	No		To treat Helicobacter pylori infection To treat certain classes of obstructive
Eamzyos	mavacamten	28-Apr-22	Yes	Submitted January 2022	hypertrophic cardiomyopathy
					To reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females
					with a history of RVVC who are not of
∎ivjoa	oteseconazole	26-Apr-22	No		reproductive potential
	lutetium (177Lu) vipivotide				To treat prostate-specific membrane antige positive metastatic castration-resistant
Pluvicto	tetraxetan	23-Mar-22	Yes	Issued NOC in August 2022	prostate cancer following other therapies
					To treat unresectable or metastatic
D pdualag	nivolumab and relatlimab-rmbw	18-Mar-22	Yes	New active substance	melanoma
⊉ talmy	ganaxolone	18-Mar-22	No		To treat seizures in cyclin-dependent kinas like 5 deficiency disorder
	Series Se				To treat intermediate or high-risk primary of
					secondary myelofibrosis in adults with low
Monjo	pacritinib	28-Feb-22	No		platelets To treat hemolytic anemia in pyruvate kina
Byrukynd	mitapivat	17-Feb-22	No		deficiency
					To decrease the need for red blood cell
E njaymo	Butimlimab-jome	04-Feb-22	No		transfusion due to hemolysis in cold agglutinin disease
Enjayino	and minimab-joine	01-160-22	140		To treat neovascular (wet) aged-related
					macular degeneration and diabetic macula
₩abysmo	faricimab-svoa	28-Jan-22	Yes	NOC May 2022	edema To treat unresectable or metastatic uveal
Kimmtrak	tebentafusp-tebn	25-Jan-22	Yes	Issued NOC June 2022	melanoma
				New active substance	
				Part of 'aligned review' with a	
Cibinna	abrocitinib	14 1 22	V	health technology assessment organization	To treat refractory, moderate-to-severe
Cibingo Quviviq	daridorexant	14-Jan-22 07-Jan-22	Yes Yes	Submitted October 2021	atopic dermatitis To treat insomnia
					To treat moderate-to-severe atopic
Adbry	Eralokinumab-ldrm	27-Dec-21	Yes	Issued NOC in October 2021	dermatitis
Bi.	inclisiran	22-Dec-21	Yes	NOC July 2021	hypercholesterolemia or clinical atherosclerotic cardiovascular disease as a
Eeqvio Vyvgart	efgartigimod alfa-fcab	22-Dec-21 17-Dec-21	Yes	New active substance	To treat generalized myasthenia gravis
, ,					To treat severe asthma as an add-on
Tezspire	tezepelumab-ekko	17-Dec-21	Yes	Submitted October 2021	maintenance therapy
					To treat post-transplant cytomegalovirus (CMV) infection/disease that does not
					respond (with or without genetic mutation
					that cause resistance) to available antiviral
Livtencity	maribavir	23-Nov-21	Yes	Submitted March 2022	treatment for CMV To improve growth in children five years of
					age and older with achondroplasia and ope
Voxzogo	vosoritide	19-Nov-21	No		epiphyses
					Bo treat polycythemia vera, a blood disease
Besremi	ropeginterferon alfa-2b-njft	12-Nov-21	No		that causes the overproduction of red bloc cells
000000	Topegment and 25 tijn	22.101.22			To treat Philadelphia chromosome-positive
					chronic myeloid leukemia with disease tha
Scemblix	asciminib	29-Oct-21	Yes	Submitted August 2021	meets certain criteria uo treat severe active anti-neutrophii
					cytoplasmic autoantibody-associated
Tavneos	avacopan	07-Oct	Yes	Submitted May 2021	vasculitis (granulomatosis with polyangiitis To treat cholestatic pruritus associated wit
Eivmarli	maralixibat	29-Sep-21	Yes	Priority Review Jan. 2023	Alagille syndrome
Qulipta	atogepant	28-Sep-21	Yes	Submitted July 2021	Bo prevent episodic migraines
					To treat recurrent or metastatic cervical
⊞vdak	Bsotumab vedotin-tftv	20-Sep-21	No		cancer with disease progression on or afte chemotherapy
us riidh.	DOCUMED FEGORIFULLY	20-зер-21	.40		
					To treat locally advanced or metastatic no
Eulidean		45.0 21			small cell lung cancer with epidermal grow
Exkivity	mobocertinib	15-Sep-21	No		factor receptor exon 20 insertion mutation
					Bo treat short stature due to inadequate
Skytrofa	Enapegsomatropin-tcgd	25-Aug-21	No		secretion of endogenous growth hormone
					Bo treat moderate-to-severe pruritus associated with chronic kidney disease in
Korsuva	difelikefalin	23-Aug-21	Yes	Submitted October 2021	certain populations
					To treat von Hippel-Lindau disease under
Melireg Newsparen	belzutifan	13-Aug-21	Yes	Submitted September 2021.	Certain conditions
Nexviazyme	avalglucosidase alfa-ngpt	06-Aug-21	Yes	Submitted November 2020	To treat late-onset Pompe disease
					To treat moderate-to severe systemic lupu
Saphnelo	anifrolumab-fnia	30-Jul-21	Yes	Submitted December 2020	erythematousus along with standard there
	odevixibat	20.1	Yes	Being reviewed under the Priority	To treat pruritus
Buluan	Juevikipat	20-Jul-21	Tes	Review Policy Submitted January 2021. Being	To treat pruritus Bo treat chronic graft-versus-host disease
Bylvay				reviewed under the Priority	after failure of at least two prior lines of
Bylvay					
Bylvay Bezurock	belumosudil	16-Jul-21	Yes	Review Policy	systemic therapy
	belumosudil	16-Jul-21	Yes	Review Policy	To treat human African trypanosomiasis
	belumosudil fexinidazole	16-Jul-21 16-Jul-21	Yes No	Review Policy	To treat human African trypanosomiasis caused by the parasite Trypanosoma bruce gambiense
Bezurock				Review Policy	To treat human African trypanosomiasis caused by the parasite Trypanosoma bruce gambiense Bo reduce the risk of kidney and heart
Bezurock				Review Policy Submitted April 2021	To treat human African trypanosomiasis caused by the parasite Trypanosoma bruce gambiense



					Bo treat acute lymphoblastic leukemia and
					lymphoblastic lymphoma in patients who are
					allergic to E. coli-derived asparaginase
	Asparaginase erwinia				products, as a component of a chemotherapy
Bylaze	chrysanthemi (recombinant)-rywn	30-Jun-21	Yes	Submitted September 2021.	regimen
Aduhelm	aducanumab-avwa	07-Jun-21	Yes	Submitted June 2021	To treat Alzheimer's disease
Brexafemme	ibrexafungerp	01-Jun-21	No		To treat vulvovaginal candidiasis To treat schizophrenia and certain aspects of
Lybalvi	olanzapine and samidorphan	28-May-21	No		bipolar I disorder
-				Being reviewed under the Notice	
				of Compliance with Conditions	To treat cholangiocarcinoma whose disease
Bruseltiq	infigratinib⊞	28-May-21	Yes	Guidance Being reviewed under the Notice	meets certain criteria
				of Compliance with Conditions	
Lumakras	sotorasib	28-May-21	Yes	Guidance	To treat types of non-small cell lung cancer
					To treat a subset of non-small cell lung
Rybrevant	amivantamab-vmjw	21-May-21	Yes	Submitted July 2021	cancer
Empaveli	pegcetacoplan	14-May-21	Yes	Submitted Mar. 2023	To treat paroxysmal nocturnal hemoglobinuria
	p-g				To treat certain types of relapsed or
Z ynlonta	Boncastuximab tesirine-lpyl	23-Apr-21	No		refractory large B-cell lymphoma
				Submitted April 20201. Being	
				reviewed under the Notice of Compliance with Conditions	
Jemperli	dostarlimab-gxly	22-Apr-21	Yes	Guidance	To treat endometrial cancer
Nextstellis	drospirenone and estetrol tablets	15-Apr-21	Yes	NOC March 2021	To prevent pregnancy
					For the treatment of attention deficit
Delbree	viloxazine	02-Apr-21	No		hyperactivity disorder
Degalogue	dasiglucagon	22-Mar-21	No		To treat severe hypoglycemia
_					To treat patients with relapsing forms of
Bonvory	ponesimod	18-Mar-21	Yes	Submitted June 2020	multiple sclerosis
Eptivda	tivozanib	10-Mar-21	No		To treat patients with renal cell carcinoma
ED U VUO	serdexmethylphenidate and	20 11101 22			For the treatment of Attention Deficit
Azstarys	dexmethylphenidate	02-Mar-21	No		Hyperactivity
					For the treatment of certain patients with
Pepaxto	melphalan flufenamide®	26-Feb-21	No		relapsed or refractory multiple myeloma
					To treat patients with the rare genetic disease molybdenum cofactor deficiency
Nulibry	fosdenopterin	26-Feb-21	No		Type A
•	•				For the treatment of Duchenne muscular
Amondys 45	casimersen	25-Feb-21	No		dystrophy
					To mitigate chemotherapy-induced
Cosela	trilacicilib	12-Feb-21	No		myelosuppression in adult patients with small cell lung cancer
Coseia	dilaciciiib	12-1-60-21	140		For the treatment of homozygous familial
Evkeeza	evinacumab-dgnb	11-Feb-21	Yes	Issued NOC in Sept. 2023	hypercholesterolemia
					For the treatment of certain patients with
					marginal zone lymphoma and follicular
Ukoniq Eepmetko	umbralisib tepotinib	05-Feb-21 03-Feb-21	No Yes	Submitted December 2020	lymphoma To treat non-small cell lung cancer
Eupkynis	voclosporin	22-Jan-21	No	Submitted December 2020	To treat lupus nephritis
Babenuva	cabotegravir and rilpivirine	21-Jan-21	Yes	Issued NOC in April 2020	To treat HIV
Verquvo	vericiguat	19-Jan-21	Yes	Submitted January 2021	To treat chronic heart failure
Gemtesa	vibegron	23-Dec-20			To treat overactive bladder
Ebanga	ansuvimab-zykl	21-Dec-20	No	N	To treat Ebola
Orgovyx Margenza	relugolix margetuximab (anti-HER2 mAb	18-Dec-20 16-Dec-20	Yes No	New active substance	To treat advanced prostate cancer To treat HER2+ breast cancer
	arge towning (difference made	10-560-20			
Klisyri	tirbanibulin	14-Dec-20	Yes	Submitted July 2022	To treat actinic Keratosis of the face or scalp
Orladeyo	berotralstat	03-Dec-20	Yes	Submitted August 2021	To treat patients with hereditary angioedem.
Danyelza	naxitamab-gqgk	25-Nov-20	No		To treat high-risk refractory or relapsed neuroblastoma
Dailyeiza	Havirailian-Edek	25-NOV-20	NO		mean obligation in
					To treat obesity and the control of hunger
					associated with pro-opiomelanocortin
_					deficiency, a rare disorder that causes severe
Encivree Parkers	Setmelanotide	25-Nov-20	Yes	New active substance	obesity that begins at an early age
Dxlumo	lumasiran	23-Nov-20	Yes	Submitted August 2021	To treat hyperoxaluria type 1 To treat rare conditions related to premature
B okinvy	lonafarnib	20-Nov-20	No		aging
					FDA: To treat COVID-19 HC
Meklury	remdesivir	22-Oct-20	Yes	NOC July 2020	Antivirals for systemic use
	atoltivimab, maftivimab, and	***			To be a both of the
Ehmazeb Gavreto	odesivimab-ebgn pralsetinib	14-Oct-20 04-Sep-20	No Yes	Submitted November 2020	To treat ebola virus To treat non-small lung cancer
Odvieto	Praiseruno	∪4-sep-20		Submitted November 2020	To treat non-small lung cancer To treat neuromyelitis optica spectrum
Enspryng	satralizumab-mwge	14-Aug-20	Yes	Issued NOC in June 2020	disorder
Viltepso	viltolarsen	12-Aug-20	No		To treat Duchenne muscular dystrophy
Olinvyk	oliceridine	07-Aug-20	No	0.1-3-10-10-1	To manage acute pain in certain adults
Evrysdi	risdiplam	07-Aug-20	Yes	Submitted Oct. 2020, under review	To treat spinal muscular atrophy To treat Chagas disease in certain pediatric
Lampit	nifurtimox	06-Aug-20	No		patients younger than age 18
Blenrep	belantamab mafodotin-blmf)	05-Aug-20	No		To treat multiple myeloma
			Yes		To treat relapsed or refractory diffuse large E
Monjuvi	tafasitamab-cxix⊡	31-Jul-20		Submitted December 2020	cell lymphoma
Incomi	decitabine and codeswriding	07 lun 20	Yes	NOC July 2020	To treat adult patients with myelodysplastic
Inqovi	decitabine and cedazuridine	07-Jun-20		NOC July 2020	syndromes

Bylandom Options of emissecolum Options of emissecolum Options
Bejohel commonisorium (0.0.m.0) Ne yes Submitted August 2000 controller for the rest motionality into phosin flat yes of the section of the s
Bejohe vinlegstannin 30-ium 20 Zepacka urbinisctudim 15-ium 20 Vest Submitted August 2020 on disclaim discourage of unidential microscillary in control and in the property of the property
Bejolet inhipperation 30-bm-30 Yes Submitted Agent 2000 oxidation disorders 2 years and call lung cancer 30 years are set of the set
Topical part Telephone Topical part Topical
Appendix Appendix Inchingence Inching
Uplatina inshiftirumabirdon 11-lun-20 No Travan neuromynistic optica spectrum discontrate 26-May-20 No Ves Submitted March 2020, INCC Lune Contract
Opinion
Artesunate artesunate 26 May-20 No Submitted March 2000, NOC Lura 2 Tumors Glinick ryvetinib 13-44y-20 Yes Submitted March 2000, NOC Lura 2 Tumors Flatevino esperatinib 64-4ay-20 Yes conditions guidance 7 To vera department on small cell light of the conditions guidance 7 To vera department on small cell light of the conditions guidance 7 To vera department with Parkinson's disease on Congenty opiciagons 24-4ay-20 Yes Submitted September 2001. To vera department with Parkinson's disease on Congenty opiciagons 24-4ay-20 Yes Submitted September 2001. Troubley accitusumab govitican huly 22-4ay-20 Yes Submitted March 2001 to vera form a patients with mon small cell light of the conditions guidance 7 To vera sobal patients with Parkinson's disease on Congenty 24-4ay-20 Yes Submitted March 2001 to vera certain patients with measurate trip register breast cancer who received at le non-prior the factors with received at le non-prior the factors with received at le non-prior the factors with received at le non-prior the factors in the condition of th
Qinilock reportinis 15.44y-20 Yes Submitted March 2010, MCC, Jun 2 tumors of the second control of the second
Geleck rypertion 15-May-20 Yes Submitted March 2000, INCC June 2 Submitted September 2001 To was present with Parkinson's disease. Talvetta caparatinib O6-May-20 Yes Submitted September 2021. To was pointes with Parkinson's disease. Organity opicagone 24-Apr-20 No Submitted September 2021. To was pointes with Parkinson's disease. Organity Opicagone 24-Apr-20 Yes Submitted September 2021. To was pointes with Parkinson's disease. Organity Opicagone 24-Apr-20 Yes Submitted March 2021 To was pointes with Parkinson's disease. To row as department of the parkinson's disease. To row as pointes with Parkinson's disease. To row as certain patients with reactive to report the Parkinson's disease. To row as certain patients with reactive to report the Parkinson's disease. To row as certain patients with reactive to report the Parkinson's disease. To row as certain patients with reactive to report the Parkinson's disease. To row as certain patients with reactive to report the Parkinson's disease. To row as certain patients with reactive to report the Parkinson's disease. To row as certain patients with reactive to report the Parkinson's disease. To row as certain patients with reactive to report the Parkinson's disease. To row as certain patients with reactive the reactive to report the Parkinson's disease. To row as certain patients with reactive the reactive to report the reactive the reactive to report the reactive th
Retermo sulpercatinib 06-May-20 Talvecta capmatinib 06-May-20 Ves Submitted September 2021. Cancer To treat patients with non small cell lung cancers operation operations of the september 2021. Cancer To treat patients with Parkson's disease experiencing of Paysboorts disease experiencing disease. Paysboorts disease experiencing disease experiencing disease experiencing disease experiencing disease. Paysboorts disease experiencing disease experiencing disease experiencing disease. Paysboorts disease experiencing disease experienci
Retermo spipercatinib 06-May-20 Talvecta capmatinib 06-May-20 Ves Submitted September 2021. Cancer To treat patients with non small cell lung cancer To treat patients with non small cell lung cancer To treat patients with Prakhason's disease experiencing of Propisions Propision opiciopone 24-6p-20 No Submitted September 2021. Cancer To treat patients with Prakhason's disease experiencing of Propisions To treat adulty patients with metastactive in negative scarcer with received at let the principle of the received at let the principle scarcer with received scarcer w
Retermo opporationib 06-May-20 Yes conditions guidance B treat lung and thrycotd cancer opporation operation 06-May-20 Yes Submitted September 2021. To treat agrients with no small cell lung cancer opporation operation operation of the september 2021. To treat agrients with Parkinson's disease operation of the september 2021. To treat agrients with Parkinson's disease operation of the september 2021. To treat agrients with Parkinson's disease operation of the september 2021. To treat agrients with Parkinson's disease operation operation operation operation operation of the september 2021. To treat certain patients with challenges on the september 2021 operation operation operation with challenges on the september 2021 operation operation operation with challenges operation operation operation of the september 2022 operation operation operation with challenges operation oper
Talvecta opinatinib 06-Map-20 Yes Submitted September 2021. Circle patients with non small cell lung opination opina
Ongestys opicagenee 24-Apr 20 No experiments with Parkinson's disease experiments of the process
Ongentys opicagone 24-Apr 20 No experiments with Parkinson's disease experiments of the process
Ongentys opicapone 2-9-4pr-20 No experiencing "Off epitodes To treat adult padients with metastatic trip." Trodeby salumatina povitecan-holy 2-2-4pr-20 Yes Submitted March 2021 to prot thereighte for metastatic disparation of Cancelland Programs of Can
Trodelvy sacturumab govitecan-haly 22.4p-20 Yes Submitted March 2021 to repetite hereat cancer who received at it to perform the past of the cancer who received at it to perform the past of the cancer who received at it to perform the past of the cancer who received at it to perform the past of the cancer who received at it to perform the past of the cancer who received at it to perform the past of the cancer who received at it to perform the cancer who cancer who received at it to perform the cancer who cancer who received at it to perform the cancer who cancer who received at it to perform the cancer who cancer who received at it to perform the cancer who can
Trodelny sacinus meb govites an haly 22.4 pc 20 Pennaryre pennigatinib 17.4 pc 20 Pennaryre pennaryre pennigatinib 17.4 pc 20 Pennaryre pennaryre pennaryre pennigation pennaryre
Trodelwy sacturumab govinecan haly 22.4 pg-20 Femaryre pemigstrisib 17.4 pr-20 Femaryre pemigstrisib 17.4 pr-20 Fullyris tocation 17.4 pr-20 Fullyris to
Trodeley softwarmab govitecan-haby 2-2-Apr-20 Yes Submitted March 2021 To treat certain patients with cholangiocarcinoma, a rare form of cance the foliance of the discretism
Pemaryre pernigatinib 17-apr-20 Yes Submitted Oct. 2020 that forms in his ducts that forms in graine thad forms in graine that forms in graine that forms in graine that
Pemaryre pemigatinib 17-Apr-20 Yes Submitted Oct. 2020 that from in this discuss Trakyra trustation 17-Apr-20 yes NDS rebrary 2020 (priority review). Advanced unresectable or metastatis HEE2-VER Control of the Apr-20 yes NDS rebrary 2020 (priority review). Advanced unresectable or metastatis HEE2-VER Control of the Apr-20 yes NDS rebrary 2020 (priority review). Advanced unresectable or metastatis HEE2-VER Control of the Apr-20 yes NDS rebrary 2020 (priority review). Advanced unresectable or metastatis HEE2-VER Control of the Apr-20 yes NDS rebrary 2020 (priority review). Advanced unresectable or metastatis HEE2-VER Control of the Apr-20 yes NDS rebrary 2020 (priority review). Advanced unresectable or metastatis HEE2-VER Control of the Apr-20 yes NDS rebrary 2020 (priority review). Advanced unresectable or metastatis HEE2-VER Control of the Apr-20 yes NDS rebrary 2020 (priority review). Advanced unresectable or metastatis HEE2-VER Control of the Apr-20 yes NDS rebrary 2020 (priority review). Advanced unresectable or metastatis HEE2-VER Control of the Apr-20 yes NDS rebrary 2020 (priority review). Advanced unresectable or metastatis HEE2-VER Control of the Apr-20 yes NDS rebrary 2020 (priority review). Advanced unresectable or metastatis HEE2-VER Control of the Apr-20 yes NDS rebrary 2020 (priority review). Advanced unresectable or metastatis HEE2-VER Control of the Apr-20 yes NDS rebrary 2020 (priority review). Advanced unresectable or metastatis HEE2-VER Control of the Apr-20 yes NDS rebrary 2020 (priority review). Advanced unresectable or metastatis HEE2-VER Control of the Apr-20 yes NDS rebrary 2020 (priority review). Advanced unresectable or metastatis HEE2-VER Control of the Apr-20 yes NDS rebrary 2020 (priority review). Advanced unresectable or metastatis HEE2-VER Control of the Apr-20 yes NDS rebrary 2020 (priority rebrary 2
Penaryre penigatinib 12-Apr-20 Yes Submitted Oct. 2020 shart forms in bile dictors Audinord unsersativit FEE2- Tulkyra tustinib 17-Apr-20 yes ND5 February 2020 [priority review], Proceedings of the nervous system causing tumont to grow of the nervous system causing tumor of multiple sclerosis. Nurse CVP in December 2019 Audition of the nervous system causing tumor of multiple sclerosis. Nurse CVP in December 2019 Audition of the nervous system causing tumor of multiple sclerosis. Nurse CVP in December 2019 Audition of the nervous system causing tumor of multiple sclerosis. Nurse CVP in December 2019 Audition of the nervous system causing tumor of multiple sclerosis. Nurse CVP in December 2019 Audition of the nervous system causing tumor of multiple sclerosis. Nurse CVP in December 2019 Audition of the nervous system causing tumor of multiple sclerosis. Nurse CVP process of the nervous system causing tumor of multiple sclerosis. Nurse CVP process of the nervous system causing tumor of mult
Tulypa turatinib 17-Ap-20 yes NDS February 2020 (priority review), A positive breast cancer restrict REE2- Koselugo sulumetinib 10-Ap-20 Yes Submitted November 2020 enves the nervous system casing tumors to grow cheese and sultimated to assist the nervous system casing tumors to grow cheese and sultimated to assistance of the nervous system casing tumors to grow cheese and sultimated to assistance of the nervous system casing tumors to grow cheese and sultimated to assistance of the nervous system casing tumors to grow cheese and sultimated to assistance of the nervous system casing tumors to grow cheese and sultimated the nervous system casing tumors to grow cheese substance. Section 3 case of the nervous system of the nervous system of the nervous system casing tumors of multiple sciencis. Section 3 case of the nervous system of the nervous system of the nervous system of multiple sciencis. Nertec CDT trengpant (27-de-20 Yes Canchede by sponsor in 2021 New Multiple systems and vomining disparance of the nervous systems of the nervous s
Tukyra tucrininb 12-Apr-20 yes NDS February 2020 [priority review], a positive breast cancer Neurofibromatoris by e 1, a genetic disorder the nervous system causing tumors to grow cannot control to the control of the
Koselugo selumetinib 10-Apr-20 Ves Submitted November 2020 nerve Neuroriformatosis type 1, a genetic disorder the nervous system causing tumors to grow of the nervous system causing tumors of the nervous system causing tumors to grow of the nervous system causing system causing system causing system causing system causing system causi
Koselugo selumetinib 10-Apr-20 Yes Submitted November 2020 nerves Zeposia caraimod 23-Mar-20 Yes NoS in December 2019 Alejasing forms of multiple sciencis strutisa collodrostat 06-Mar-20 Yes NoS in December 2019 Alejasing forms of multiple sciencis Sarcikia collodrostat 06-Mar-20 Yes NoS in December 2019 Alejasing forms of multiple sciencis Sarcikia statusinab-iric 03-Mar-20 Yes NoS and year 2019, NOC April 2020 Nutriple Myeloma 12-7-7-6b-20 Yes NoS and year 2019, NOC April 2020 Nutriple Myeloma Multiple Myeloma 24-7-7-6b-20 Yes Cancolled by sponsor in 2021 Tasues and vomiting the process of the pro
Roselugo selumetrinib 10-Apr-20 ves Submitted November 2020 nerves carried 22-Mara-20 25-Mara-20 ves Nos December 2020 felaping forms of multiple scienosis Isturisa oxidodrostat 0.64-Mar-20 ves Nos December 2021 felaping forms of multiple scienosis Isturisa oxidodrostat 0.64-Mar-20 ves Nos December 2021 felaping forms of multiple scienosis Isturisa oxidodrostat 0.64-Mar-20 ves Nos Astronomical Continue (Continue Continue C
Zeposia Casimined 25-Mar-20 Yes NDS in December 2019 Religioning forms of multiple sclerosis Sarclisa Go-Mar-20 Yes Na active substance Cushing's disease Sarclisa Sarchisa
Sarcias disturinambeirc O3-Mara-20 yes No was citive subtract per Country disease Sarcinas disturinambeirc O3-Mara-20 yes No Sulvy 2019, NOC Appl 2020 Multiple Myeleoma Multiple Myeleoma Multiple (Appl 2020) Multipl
Sarclisa Satusimab-irk
Nurse ODT Imnegepant 27-96-20 Yes New active substrance Migraine
Barhemsys amisulpride 26-Feb-20 Yes Cancelled by sponsor in 2021 Nauses and voniting Vyepti eptinezumab-jimr 21-Feb-20 Yes Submitted March 2020 Migraine Nexletol bempedoic acid 21-Feb-20 No established atheroscierotic CV disease Pizensy lactitol 12-Feb-20 No Chronic idiopathic constipation (ICI) in adult Tarverilk tazemetostat 22-Jan-20 No To treat epitheloid starcoma Tepezza teprotumumab-trbw 21-Jan-20 No To treat politheloid starcoma Ayvakit avapritinib 09-Jan-20 No To treat politheloid starcoma Tupezza teprotumumab-trbw 21-Jan-20 No To treat politheloid starcoma Ayvakit avapritinib 09-Jan-20 No Established atheroscierotic CV disease Ayvakit avapritinib 09-Jan-20 No To treat politheloid starcoma Tupezza teprotumumab-trbw 21-Jan-20 No To treat thryroid eye disease Ayvakit avapritinib 09-Jan-20 No Established atheroscierotic CV disease Ayvakit avapritinib 09-Jan-20 No To treat thryroid eye disease To treat adults with unresectable or metastate gastrointestinal stromal tumori (cST) Ulruelvy abrogapant 23-Dec-19 Yes Submitted October 2021 Wited acute treatment of migraine with or treat acute treatment of migraine with or treat complete treatment of migraine with or treatment of anemia in adult patients with branched and scale and treatment of treatment of anemia in adult patients of treatment of anemia i
Vyepti
Nexisto bempedoic acid 21-feb-20 No heterocrygous familial hypercholesterolemia established atherosclerotic CV disease Pizensy lactitol 12-feb-20 No Chronic idiopathic constipation (ICI) in adults Taxeetik tazemetorat 23-ian-20 No To treat pitheliolid sarcoma Tepezza teprotumumab-tribw 21-ian-20 No To treat pitheliolid sarcoma Tepezza teprotumumab-tribw 21-ian-20 No To treat thyroid eye disease Ayvakit avapritinib 09-ian-20 No To treat thyroid eye disease Ayvakit avapritinib 09-ian-20 No cartorinibation (ICI) in adults District thyroid eye disease To treat adults with unresectable or metastat cartorinibation (ICI) in adults To treat adults with unresectable or metastat cartorinibation (ICI) in adults To treat adults with unresectable or metastat cartorinibation (ICI) in adults To treat adults with unresectable or metastat cartorinibation (ICI) in adults To treat adults with unresectable or metastat cartorinibation (ICI) in adults To treat adults with unresectable or metastat cartorinibation (ICI) in adults To treat adults with unresectable or metastat cartorinibation (ICI) in adults To treat adults with unresectable or metastat cartorinibation (ICI) in adults To treat adults with unresectable or metastat cartorinibation (ICI) in adults To treat adults with unresectable or metastate cartorinibation (ICI) in adults To treat adults with unresectable or metastate cartorinibation (ICI) in adults To treat acute hepatic unresectable or metastate cartorinibation (ICI) in adults To treat acute hepatic unresectable or metastate variorinibation (ICI) in adults To treat acute hepatic unresectable or metastate variorinibation (ICI) in adults To treat acute hepatic unresectable or metastate variorinibation (ICI) in adults To treat acute hepatic unresectable or metastate variorinibation (ICI) in adults To treat acute hepatic unresectable or metastate variorinibation (ICI) in adults To treat acute hepatic unresectable or metastate variorinibation (ICI) in adults To treat acute hepatic unresectable or
Nexitetol Dempedoic acid 2.1-Feb-20 No established atherosclerotic CV disease
Nexletol Dempedoic acid 2.1-feb-20 No established atherosclerotic CV disease
Pizensy lactitol 12-Feb-20 No Chronic idiopathic constipation (CIC) in adults Tazwerik tazemetostat 23-Jan-20 No To treat epithelioid sarcoma Tepezza teprotumunab-trbw 21-Jan-20 No To treat thyroid eye disease To treat thyroid eye disease To treat thyroid eye disease To treat adults with unresectable or metastat Ayvakit avapritnib 09-Jan-20 No gastionitestinal stromal tumor (GIST) to treat adults with unresectable or metastat pastionitestinal stromal tumor (GIST) to treat acute treatment of migraine with or without aura in adults to treat acute treatment of migraine with or without aura in adults to treat acute treatment of migraine with or without aura in adults to treat acute treatment of migraine with or without aura in adults to treat acute treatment of migraine with or without aura in adults to treat acute treatment of migraine with or without aura in adults to treat acute treatment of migraine with or without aura in adults to treat acute treatment of migraine with or without aura in adults to treat acute treatment of migraine with or without aura in adults to treat acute treatment of migraine with or without aura in adults to treat acute treatment of migraine with or without aura in adults to treat acute treatment of migraine with or treat acute treatment of migraine with or treat refractory bladder cancer 10-padev enfortumab vedorin-ejfv 18-Dec-19 Yes Submitted May 2021 To treat refractory bladder cancer 19-padev enfortumab vedorin-ejfv 19-padev 1
Tarverik tasemetotat 23-ian-20 No To treat epithelioid sarcoma Tepezza teprotumumab-trbw 21-ian-20 No To treat aphthelioid sarcoma Topezza teprotumumab-trbw 21-ian-20 No To treat aphthelioid sarcoma Topezza teprotumumab-trbw 21-ian-20 No To treat adults with unresectable or metastal gatrointestinal stronal tumor (cist7) Ubreky ubrogepant 23-Dec-19 Yes Submitted October 2021 without arrain adults Enhertu fam-trastrumab derustecan-nxisi 20-Dec-19 Yes NDS (2017/18) and SNDS (Sept 2019) To treat metastatic breast cancer Dayvigo lemborexant 20-Dec-19 Yes NDS January 2020 To treat metastatic breast cancer Caplyta lumateperone toxylate 20-Dec-19 No To treat schizophrenia Padcev enfortumab vedotin-ejfv 10-Dec-19 Yes Submitted May 2021 To treat retrain patients with Duchenne Myondys 53 golodissen 10-Dec-19 No muscular dystrophy Oxbryta voxelotor 23-Nov-19 No muscular dystrophy Cobryta voxelotor 23-Nov-19 No Submitted July 2022 To treat partial onset seizures To treat acute hepatic prophysia, a rare blood Gilvarian goosiran 20-Nov-19 Yes Submitted April 2020. NOC October 20 disorder To treat patients with paintul complication of sickle cell disease To treat patients with paintul complication of sickle cell disease To treat patients with paintul complication of sickle cell disease To treat patients with paintul complication of sickle cell disease To treat patients with complicated urinary treatment of points To treat patients with mantic cell submitted April 2020. NOC October 20 disorder To treat patients with mantic cell submitted or no alternative for the treatment of points To treat patients with complicated urinary treatment of points in a dulty patient with beta thalassemia with or equire regular results and the patients with mantic cell submitted april 2020. NOC April 2020. NOC Lance patients with mantic cell for treat patients with complicated urinary treatment of amenia in adulty patients with beta thalassemia with or treat patients with or treat patients with or not patients with or treat patients with norm of b
Tarverik tasemetotat 23-ian-20 No To treat epithelioid sarcoma Tepezza teprotumumab-trbw 21-ian-20 No To treat aphthelioid sarcoma Topezza teprotumumab-trbw 21-ian-20 No To treat aphthelioid sarcoma Topezza teprotumumab-trbw 21-ian-20 No To treat adults with unresectable or metastal gatrointestinal stronal tumor (cist7) Ubreky ubrogepant 23-Dec-19 Yes Submitted October 2021 without arrain adults Enhertu fam-trastrumab derustecan-nxisi 20-Dec-19 Yes NDS (2017/18) and SNDS (Sept 2019) To treat metastatic breast cancer Dayvigo lemborexant 20-Dec-19 Yes NDS January 2020 To treat metastatic breast cancer Caplyta lumateperone toxylate 20-Dec-19 No To treat schizophrenia Padcev enfortumab vedotin-ejfv 10-Dec-19 Yes Submitted May 2021 To treat retrain patients with Duchenne Myondys 53 golodissen 10-Dec-19 No muscular dystrophy Oxbryta voxelotor 23-Nov-19 No muscular dystrophy Cobryta voxelotor 23-Nov-19 No Submitted July 2022 To treat partial onset seizures To treat acute hepatic prophysia, a rare blood Gilvarian goosiran 20-Nov-19 Yes Submitted April 2020. NOC October 20 disorder To treat patients with paintul complication of sickle cell disease To treat patients with paintul complication of sickle cell disease To treat patients with paintul complication of sickle cell disease To treat patients with paintul complication of sickle cell disease To treat patients with complicated urinary treatment of points To treat patients with mantic cell submitted April 2020. NOC October 20 disorder To treat patients with mantic cell submitted or no alternative for the treatment of points To treat patients with complicated urinary treatment of points in a dulty patient with beta thalassemia with or equire regular results and the patients with mantic cell submitted april 2020. NOC April 2020. NOC Lance patients with mantic cell for treat patients with complicated urinary treatment of amenia in adulty patients with beta thalassemia with or treat patients with or treat patients with or not patients with or treat patients with norm of b
Tepezza teprotumumab-trbw 21-jan-20 No To treat adults with unresectable or metastal Ayvakit avapritinib 09-jan-20 No To treat adults with unresectable or metastal gastrointestinial stromal tumor (pist') to treat actue treatment of migraine with or without aura in adults patrointestinial stromal tumor (pist') to treat actue treatment of migraine with or without aura in adults or treat metastatic breast cancer Dayvigo temborexant 20-Dec-19 yes NDS (patry/18) and SNDS (sept.2019) To treat metastatic breast cancer Obayvigo temborexant 20-Dec-19 ND To treat refractory bladder cancer To treat or extrain patients with Duchenne Muscular dystrophy and the patrial cancer To treat certain patients with Duchenne Muscular dystrophy Oxbryta voxelotor 25-Nov-19 ND To treat restation and the patrial cancer Submitted July 2022 To treat patrial notate setures To treat actue the patrix polyphy Oxbryta voxelotor 25-Nov-19 ND To treat certain patients with Duchenne Muscular dystrophy To treat patrial notate setures To treat actue the patrix polyphy Oxbryta voxelotor 25-Nov-19 ND To treat patrial notate setures To treat actue the patrix polyphy Oxbryta voxelotor 25-Nov-19 ND To treat actue the patrix polyphy in the patrial patients with painful complication of sickie cell disease To treat patients with painful complication of sickie cell disease To treat patients with painful complication of sickie cell disease To treat patients with painful complication of sickie cell disease To treat patients with complicated urinary treatment options of sickie cell disease To treat patients with complicated urinary treatment options of sickie cell disease To treat patients with complicated urinary treatment options of sickie cell disease To treat patients with complication of sickie cell disease To treat patients with complication of s
Ayvakit avapritinib 09-Jan-20 No gastrointestinal stromal tumor (GIST) Ubrelvy ubrogepant 23-Dec-19 Yes Submitted October 2021 without are in adults Enhertu fam-trastrumab deruxtecan-nxki 20-Dec-19 yes NDS (2017/18) and SNDS (Sept 2019) To treat acute treatment of migraine with or without are in adults Enhertu fam-trastrumab deruxtecan-nxki 20-Dec-19 yes NDS (2017/18) and SNDS (Sept 2019) To treat insominal cancer Dayvigo lemborecant 20-Dec-19 yes NDS (2017/18) and SNDS (Sept 2019) To treat insominal cancer To treat schizophrenia To treat schizophrenia To treat schizophrenia Padcev enfortumab vedotin-ejfv 18-Dec-19 NO To treat schizophrenia To treat certain patients with Duchene muscular dystrophy Oxbryta voxelotor 12-Nov-19 NO To treat schizophrenia Padcev Enfortumab vedotin-ejfv 18-Dec-19 NO To treat schizophrenia To treat patial onset seitures To treat schizophrenia To treat schizophrenia To treat patial onset seitures To treat patients with painful complication of sicke cell disease To treat patients with complicated urinary treatment of patients with a manuface cell schizophrenia To treat patients with manuface cell To treat patients with patients with Debot cell cell schizophrenia To treat patients with a manuface cell To treat patients with a late treatment
Ayvakit avapritinib O9-Jan-20 No Ubrelvy ubrogepant 23-Dec-19 Ves Submitted October 2021 to treat acute treatment of migraine with or without aura in adults Enhertu fan-traturumab deruxtecan-nxki 20-Dec-19 Ves ND5 (2017/18) and 5ND5 (Sept 2019) To treat treatment of migraine with or without aura in adults Enhertu Enhertu fan-traturumab deruxtecan-nxki 20-Dec-19 Ves ND Sanuary 2020 To treat schizophrenia Padcev enfortumab vedotin-ejfv 18-Dec-19 Ves Submitted May 2021 To treat schizophrenia To treat certain patients with Duchenne wuscular dystrophy To treat certain patients with Duchenne muscular dystrophy To treat schizophrenia Pot ves Xcopri cenobamate 12-Dec-19 No No To treat schizophrenia To treat s
Ayvakit avapritinib O9-Jan-20 No Ubrelvy ubrogepant 23-Dec-19 Ves Submitted October 2021 to treat acute treatment of migraine with or without aura in adults Enhertu fan-traturumab deruxtecan-nxki 20-Dec-19 Ves ND5 (2017/18) and 5ND5 (Sept 2019) To treat treatment of migraine with or without aura in adults Enhertu Enhertu fan-traturumab deruxtecan-nxki 20-Dec-19 Ves ND Sanuary 2020 To treat schizophrenia Padcev enfortumab vedotin-ejfv 18-Dec-19 Ves Submitted May 2021 To treat schizophrenia To treat certain patients with Duchenne wuscular dystrophy To treat certain patients with Duchenne muscular dystrophy To treat schizophrenia Pot ves Xcopri cenobamate 12-Dec-19 No No To treat schizophrenia To treat s
Ubrelvy ubrogepant 23-Dec-19 Yes Submitted October 2021 without aura in adults Enhertu fam-trastuzumab deruxtecan-nxki 20-Dec-19 yes NDS (2017/18) and SNDS (Sept 2019) To treat metastatic breast cancer Dayvigo lemborexant 20-Dec-19 yes NDS January 2020 To treat insomnia Caplyta lumateperone tosylate 20-Dec-19 NO To treat schicophrenia Padcev enfortumab vedotin-ejfv 18-Dec-19 Yes Submitted May 2021 To treat schicophrenia Padcev enfortumab vedotin-ejfv 18-Dec-19 Yes Submitted May 2021 To treat certain patients with Duchenne muscular dystrophy Oxbryta voxelotor 25-Nov-19 NO To treat schic cell disease Xcopri cenobamate 21-Nov-19 Yes Submitted July 2022 To treat partial onset seitures Givlaari givosiran 20-Nov-19 Yes Submitted April 2020. NOC October 2d civil disease Adakveo crizanlizumab-tmca 15-Nov-19 NO To treat patients with painful complication of sickle cell disease To treat patients with complicated urinary treatment options Fetroja cefiderocol 14-Nov-19 NO To treat patients with maniful complication of sickle cell disease To treat patients with maniful complication of sickle cell disease To treat patients with maniful complication of sickle cell disease To treat patients with maniful complication of sickle cell disease To treat patients with maniful complication of sickle cell disease To treat patients with maniful complication of sickle cell disease To treat patients with maniful complication of sickle cell disease To treat patients with maniful complication of sickle cell disease To treat patients with maniful complication of sickle cell disease To treat patients with maniful complication of sickle cell disease To treat patients with maniful complication of sickle cell disease To treat patients with maniful complication of sickle cell disease To treat patients with maniful complication of sickle cell disease To treat patients with maniful complication of sickle cell disease To treat patients with maniful complication of sickle cell disease To treat patients with maniful complication of sickle cell disease
Ubrelby ubrogepant 23-Dec-19 Yes Submitted October 2021 without aura in adults Enhertu fam-trastruzumab deruxtecan-nxki 20-Dec-19 yes NDS (2017/18) and SNDS (Sept 2019) Dayvigo lemboresant 20-Dec-19 yes NDS January 2020 To treat insomnia Caplyta lumateperone tos/late 20-Dec-19 NO To treat schizophrenia Padcev enfortumab vedotin-ejfv 18-Dec-19 Yes Submitted May 2021 To treat schizophrenia To treat certain patients with Duchenne muscular dystrophy Oxbryta voxelotor 25-Nov-19 No To treat schizophy To treat certain patients with Duchenne with Duchenne givosiran 20-Nov-19 Yes Submitted July 2022 To treat partial onset seitures Givlaari givosiran 20-Nov-19 Yes Submitted April 2020. NOC October 20 disorder Adakveo crizanlizumab-tmca 15-Nov-19 No To treat patients with painful complication of sickle cell disease To treat patients with complicated urinary treatment options Fetroja cefiderocol 14-Nov-19 No To treat patients with mantie cell scale and patients with mantie cell supplementary treatment options To treat patients with complicated urinary treatment options To treat patients with mantie cell scale and provided urinary treatment options To treat patients with mantie cell treatment options To treat patients with mantie cell scale and provided urinary treatment options To treat patients with mantie cell treatment options To treat patients with mantie cell treatment options To treat patients with mantie cell to treatment options To treat patients with mantie cell treatment options To treat patients with mantie cell to treatment of anemia in adult patients with with the tablassemia who require regular residence of the cause patients of the cause patients with or treatment of migraine with or to treat patients with a history of phototoxic reaction (damage to skin) from erythropoietic protoporphyria
Enhertu fam-trastuzumab deruxtecan-nxki 20-Dec-19 yes NDS [2017/18] and SNDS [Sept 2019] To treat metastatic breast cancer Dayvigo lemboreant 20-Dec-19 yes NDS January 2020 To treat instinania (Capitra lumateperone tosylate 20-Dec-19 NO To treat schizophrenia Padcev enfortumab vedotin-ejfv 18-Dec-19 Yes Submitted May 2021 To treat refractory bladder cancer Vyondys 53 golodirsen 12-Dec-19 NO To treat schizophrenia Oxbryta voxelotor 25-Nov-19 NO To treat sckide cell disease Xcopri cenobamate 21-Nov-19 Yes Submitted July 2022 To treat partial onset sciures Givlaari givosiran 20-Nov-19 Yes Submitted July 2020. To treat partial conset sciures Adakveo crizanlizumab-tmca 15-Nov-19 NO To treat patients with painful complication of sickle cell disease Fetroja cefiderocol 14-Nov-19 NO To treat patients with complicated urinary treinfections who have limited or no alternative freatment options To treat patients with mantle cell Brukinsa zanubrutinib 14-Nov-19 Yes Submitted September 2020. NOC Mark [ymphoma, a form of blood cancer for the treatment of anemia in adult patients with beat shalassemia who require regular results are submitted December 2020. NOC June Replaints in the most common gene mutation that cause cystic fibrosis For the acute treatment of migraine with or Reyvow lasmiditan 11-Oct-19 Yes Submitted April 2020. Cancelled by spw without aura, in adults To increace pain-free light exposure in adult patients with a history of phototoxic reaction (damage to skin) from erythropoietic protoporphyria
Dayvigo lemborexant 20-Dec-19 yes NDS January 2020 To treat insomnia Caplyta lumateperone tosylate 20-Dec-19 NO To treat schizophrenia Padcev enfortumab vedotin-ejfv 18-Dec-19 Yes Submitted May 2021 To treat refractory bladder cancer To treat certain patients with Duchenne muscular dystrophy Oxbryta voxelotor 22-Nov-19 NO To treat sickle cell disease Xcopri cenobamate 21-Nov-19 Yes Submitted July 2022 To treat partial onset seizures Givlaari givosiran 20-Nov-19 Yes Submitted April 2020. NOC October 2d disorder Adakveo crizanlizumab-tmca 15-Nov-19 NO To treat patients with painful complication of sickle cell disease To treat patients with painful complication of sickle cell disease To treat patients with painful complication of sickle cell disease To treat patients with painful complication of sickle cell disease To treat patients with painful complication of sickle cell disease To treat patients with complicated urinary treatment options Fettoja cefiderocol 14-Nov-19 No Submitted September 2020. NOC Mark Tymphoma, a form of blood cancer For the treatment of anemia in adult patients with beat thalassemia who require regular re blood cell transfusions To treat patients 12 years of age and older with beat athalassemia who require regular re blood cell transfusions To treat patients 12 years of age and older with most common gene mutation that cause. Trikafta elexacaftor/ivacaftor/tezacaftor 21-Oct-19 Yes Submitted December 2020. NOC June Cystic fibrosis For the acute treatment of migraine with or Reyvow lasmiditan 11-Oct-19 Yes Submitted April 2020. Cancelled by sp without aura, in adults For the acute treatment of migraine with or protoporphyria
Caplyta lumateperone tosylate 20-Dec-19 No To treat schizophrenia Padcev enfortumab vedotin-ejfv 18-Dec-19 Yes Submitted May 2021 To treat refractory bladder cancer To treat schizophrenia patients with Duchenne muscular dystrophy Oxbryta voxelotor 25-Nov-19 No To treat sickle cell disease Xcopri cenobamate 21-Nov-19 Yes Submitted July 2022 To treat patients with painful complication of sickle cell disease Givlaari givosiran 20-Nov-19 Yes Submitted April 2020. NOC October 2d disorder Adakveo crizanlizumab-tmca 15-Nov-19 No To treat patients with painful complication of sickle cell disease To treat patients with complicated urinary treatment options Fetroja cefiderocol 14-Nov-19 No To treat patients with mantle cell submitted September 2020. NOC Mark lymphoma, a form of blood cancer For the treatment of a nemia in a dult patients with beat halassemia who require regular reblood cell transfusions Trikafta elexacaftor/ivacaftor/tezacaftor 21-Oct-19 Yes Submitted April 2020. NOC Dune Reyvow lasmiditan 11-Oct-19 Yes Submitted April 2020. Cancelled by specific from seven patients with or protoporphyria To increase pain-free light exposure in adult patients with a history of phototoxic reaction (damage to skin) from erythropoietic protoporphyria
Padcev enfortumab vedotin-ejfv 18-Dec-19 Ves Submitted May 2021 To treat refractory bladder cancer Vyondys 53 golodirsen 12-Dec-19 No muscular dystrophy Oxbryta voxelotor 25-Nov-19 No To treat scikle cell disease Xcopri cenobamate 21-Nov-19 Ves Submitted July 2022 To treat partial onset seizures To treat acute hepatic porphyria, a rare blood Givlaari givosiran 20-Nov-19 Ves Submitted April 2020. NOC October 20 disorder Adakveo crizanlizumab-tmca 15-Nov-19 No Submitted April 2020. NOC October 20 disorder Fetroja cefiderocol 14-Nov-19 No To treat patients with painful complication of sickle cell disease To treat patients with complicated urinary treatment options Fetroja cefiderocol 14-Nov-19 No To treat patients with nametic cell disease To treat patients with complicated urinary treatment options To treat patients with complicated urinary treatment options To treat patients with nametic cell disease To treat patients with complicated urinary treatment options To treat patients with on alternative treatment options To treat patients under under under under under the patients with patients with manual cell patients with beat shalassemia who require regular re blood cancer For the treatment of anemia in adult patients with beat shalassemia who require regular re blood cancer under under under under under the most common gene mutation that cause complete the most common gene mutation that cause cystic fibrosis Trikafta elexacaftor/ivacaftor/tezacaftor 21-Oct-19 Ves Submitted December 2020. NOD June cystic fibrosis For the acute treatment of migraine with or To increase pain-free light exposure in adult patients with a history of phototoxic reaction (damage to skin) from erythropoietic protoporphyria
Vyondys 53 golodirsen 12-Dec-19 No To treat certain patients with Duchenne muscular dystrophy Oxbryta voxelotor 25-Nov-19 No To treat sickle cell disease Xcopri cenobamate 21-Nov-19 Yes Submitted July 2022 To treat partial onset seizures Givlaari givosiran 20-Nov-19 Yes Submitted April 2020. NOC October 20 disorder Adakveo crizanlizumab-tmca 15-Nov-19 No To treat patients with painful complication of sickle cell disease To treat patients with complicated urinary treatment options Fetroja cefiderocol 14-Nov-19 No To treat patients with mantle cell Brukinsa 2anubrutinib 14-Nov-19 Yes Submitted September 2020. NOC Man To treat certain patients with mantle cell Brukinsa 2anubrutinib 14-Nov-19 Yes Not Applicable as of April 2020 blood cell transfusions To treat patients with mantle cell with beat shalassemia who require regular re blood cell transfusions To treat patients with mantle cell submitted September 2020. NOC Man To treat certain patients with mantle cell with beat shalassemia who require regular re blood cell transfusions To treat patients 12 years of age and older with the most common gene mutation that cause cystic fibrosis For the accute treatment of migraine with or Submitted April 2020. Cancelled by spe without aura, in adults To increase pain-free light exposure in adult patients with a history of phototoxic reaction (damage to skin) from erythropoietic protoporphyria
Vyondys 53 golodirsen 12-Dec-19 No muscular dystrophy
Oxbryta voxelotor 25-Nov-19 No To treat sickle cell disease
Xcopri cenobamate 21-Nov-19 Yes Submitted July 2022 To treat partial onset seizures To treat acute hepatic porphyria, a rare blood Givlaari givosiran 20-Nov-19 Yes Submitted April 2020. NOC October 2d disorder Adakweo crizanlizumab-tmca 15-Nov-19 No To treat patients with painful complication of sickle cell disease To treat patients with omplicated urinary treatment options To treat patients with omplicated urinary treinfections who have limited or no alternative treatment options To treat patients with omaplicated urinary treinfections who have limited or no alternative treatment options To treat patients with omaplicated urinary treinfections who have limited or no alternative treatment options To treat patients with mantie cell submitted September 2020. NOC Marrl Imphoma, a form of blood cancer For the treatment of anemia in adult patients with beat thalassemia who require regular re blood cell transfusions Trikafta elexacaftor/ivacaftor/tezacaftor Reyvow lasmiditan 11-Oct-19 Yes Submitted December 2020. NOC June cystic fibrosis For the acute treatment of migraine with or without aura, in adults To increase pain-free light exposure in adult patients with a history of phototoxic reaction (damage to skin) from erythropoietic protoporphyria
Givlaari givosiran 20-Nov-19 Yes Submitted April 2020. NOC October 2d disorder Adakveo crizanlizumab-tmca 15-Nov-19 No To treat patients with painful complication of sickle cell disease To treat patients with complicated urinary treatment options Fetroja cefiderocol 14-Nov-19 No To treat certain patients with mantle cell Brukinsa 2anubrutinib 14-Nov-19 Yes Submitted September 2020. NOC Marl ymphoma, a form of blood cancer For the treatment of anemia in adult patients with beat plainassemia who require regular re Brukinsa 15-Nov-19 Yes Not Applicable as of April 2020 blood cell transfusions Trikafta elexacaftor/ivacaftor/tezacaftor 21-Oct-19 Yes Submitted December 2020. NOC June Reyvow lasmiditan 11-Oct-19 Yes Submitted April 2020. Cancelled by spot without aura, in adults To increase pain-free light exposure in adult patients with a history of phototoxic reaction (damage to skin) from erythropoietic protoporphyria
Givlaari givosiran 20-Nov-19 Yes Submitted April 2020. NOC October 2d disorder To treat patients with painful complication of sickle cell disease To treat patients with complicated urinary treatment options To treat patients with complicated urinary treatment options To treat patients with complicated urinary treatment options To treat reatment options To treat reatment options To treat reatment options To treat reatment options To treat retain patients with mantle cell with beat a thalassemia who require regular regula
Adakweo crizanlizumab-tmca 15-Nov-19 No Scenesse afamelanotide 08-Oct-19 No Scenesse 15-Nov Sc
Adakveo crizanlizumab-tmca 15-Nov-19 No sickle cell disease To treat patients with complicated urinary treatment options To treat patients with omalicated urinary treatment options To treat certain patients with mantle cell Brukinsa 2anubrutinib 14-Nov-19 Yes Submitted September 2020. NOC Mary hymphoma, a form of blood cancer For the treatment of anemia in adult patients with beat thalassemia who require regular re Brukinsa 2anubrutinib 14-Nov-19 Yes Not Applicable as of April 2020 blood cell transtusions Reblozyl luspatercept—aamt 08-Nov-19 Yes Not Applicable as of April 2020 blood cell transtusions Trikafta elexacaftor/ivacaftor/tezacaftor 21-Oct-19 Yes Submitted December 2020. NOC June the most common gene mutation that cause: Trikafta elexacaftor/ivacaftor/tezacaftor 21-Oct-19 Yes Submitted April 2020. Cancelled by spot without aura, in adults To increase pain-free light exposure in adult patients with a history of phototoxic reaction (damage to skin) from erythropoietic protoporphyria
Fetroja cefiderocol 14-Nov-19 No To treat patients with complicated urinary treinfections who have limited or no alternative treatment options Brukinsa zanubrutinib 14-Nov-19 Yes Submitted September 2020. NOC Mark (mphoma, a form of blood cancer For the treatment of anemia in adult patients with beta thalassemia who require regular results to the standard semial who require regular results to the standard semial and the patients with beta thalassemia who require regular results to the standard semial and the patients of the standard semial sem
Fetroja cefiderocol 14-Nov-19 No infections who have limited or no alternative treatment options Brukinsa zanubrutinib 14-Nov-19 Yes Submitted September 2020. NOC Mark Por the treatment of pitolog cancer For the treatment of blood cancer For the treatment of anemia in adult patients with hantle cell lymphoma, a form of blood cancer For the treatment of anemia in adult patients with beta thalassemain who require regular re blood cell transfusions To treat patients 12 years of age and older we the most common gene mutation that causes the most common gene mutation that causes for the acute treatment of migraine with or submitted on the most common gene mutation that causes for the acute treatment of migraine with or submitted on the most common gene mutation that causes the
Fetroja cefiderocol 14-Nov-19 No treatment options To treat certain patients with mantle cell Brukinsa zanubrutinib 14-Nov-19 Yes Submitted September 2020. NOC Mark hymphoma, a form of blood cancer For the treatment of anemia in adult patients with beta thalassemia who require regular re blood cell transfusions To treat patients 12 years of age and older with ments common gene mutation that causer Trikafta elexacaftor/ivacaftor/tezacaftor 21-Oct-19 Yes Submitted December 2020. NOC June Reyvow lasmiditan 11-Oct-19 Yes Submitted April 2020. Cancelled by spot without aura, in adults To increase pain-free light exposure in adult patients with a history of phototoxic reaction (damage to skin) from erythropoietic protoporphyria
Brukinsa zanubrutinib 14-Nov-19 Yes Submitted September 2020. NOC Mard ymphoma, a form of blood cancer for the treatment of anemia in adult patients with beta thalassemia who require regular re blood cell transfusions To treat patients 12 years of age and older with emost common gene mutation that causer. Trikafta elexacaftor/ivacaftor/tezacaftor 21-Oct-19 Yes Submitted December 2020. NOC June For the acute treatment of migraine with or Reyvow asmiditan 11-Oct-19 Yes Submitted April 2020. Cancelled by spi without aura, in adults To increase pain-free light exposure in adult patients with a history of phototoxic reaction (damage to skin) from erythropoietic protoporphyria
Brukinsa zanubrutinīb 14-Nov-19 Ves Submitted September 2020. NOC Mark (lymphoma, a form of blood cancer For the treatment of anemia in adult patients with beat thalassemia who require regular re Beblozyl (uspatercept—aamt 08-Nov-19 Ves Not Applicable as of April 2020 blood cell transfusions Trikafta elexacaftor/ivacaftor/tezacaftor 21-Oct-19 Ves Submitted December 2020. NOC June Reyvow (asmiditan 11-Oct-19 Ves Submitted April 2020. Cancelled by spot without aura, in adults To increase pain-free light exposure in adult patients with a history of phototoxic reaction (damage to skin) from erythropoietic protoporphyria
Reblozyl luspatercept—aamt 08-Nov-19 Yes Not Applicable as of April 2020 blood cell transitiosins Trikafta elexacaftor/tezacaftor 21-Oct-19 Yes Submitted December 2020. NOC June. Reyvow lasmiditan 11-Oct-19 Yes Submitted April 2020. Cancelled by spot without aura, in adults To creat patients 12 years of age and older with most common gene mutation that cause: Submitted April 2020. Cancelled by spot without aura, in adults To increase pain-free light exposure in adult patients with a history of phototoxic reaction (damage to skin) from erythropoietic protoporphyria
Reblozyl luspatercept—aamt 08-Nov-19 Yes Not Applicable as of April 2020 blood cell transfusions To treat patients 12 years of age and older with most common gene mutation that causes Trikafta elexacaftor/ivacaftor/tezacaftor 21-Oct-19 Yes Submitted December 2020. NOC June cystic fibrosis For the acute treatment of migraine with or Reyvow lasmiditan 11-Oct-19 Yes Submitted April 2020. Cancelled by spi without aura, in adults To increase pain-free light exposure in adult patients with a history of phototoxic reaction (damage to skin) from erythropoietic protoporphyria
Reblozyl uspatercept—aamt
Trikafta elexacaftor/ivacaftor/tezacaftor 21-Oct-19 Yes Submitted December 2020. NOC June the most common gene mutation that cause: cystic fibrosis Reyvow lasmiditan 11-Oct-19 Yes Submitted April 2020. Cancelled by spo
Trikafta elexacaftor/ivacaftor 21-Oct-19 Yes Submitted December 2020. NOC June cystic fibrosis Reyvow lasmiditan 11-Oct-19 Yes Submitted April 2020. Cancelled by spw without aura, in adults To increase pain-free light exposure in adult patients with a history of phototoxic reaction (damage to skin) from erythropoietic protoporphyria
Trikafta elexacaftor/ivacaftor/tezacaftor 21-Oct-19 Yes Submitted December 2020. NOC June Reyvow lasmiditan 11-Oct-19 Yes Submitted April 2020. Cancelled by spk without aura, in adults To increase pain-free light exposure in adult patients with a history of phototoxic reaction (damage to skin) from erythropoietic protoporphyria
Reyvow lasmiditan 11-Oct-19 Yes Submitted April 2020. Cancelled by spok without aura, in adults To increase pain-free light exposure in adult patients with a history of phototoxic reaction (damage to skin) from erythropoietic protoporphyria
Reyvow lasmiditan 11-Oct-19 Yes Submitted April 2020. Cancelled by specific without aura, in adults To increase pain-free light exposure in adult patients with a history of phototoxic reaction (damage to skin) from erythropoietic protoporphyria
To increase pain-free light exposure in adult patients with a history of phototoxic reaction (damage to skin) from erythropoietic protoporphyria protoporphyria
patients with a history of phototoxic reaction (damage to skin) from erythropoietic Scenesse afamelanotide 08-Oct-19 no protoporphyria
(damage to skin) from erythropoietic Scenesse afamelanotide 08-Oct-19 no protoporphyria
Scenesse afamelanotide 08-Oct-19 no protoporphyria
I cultimited May 2010, announced Treatment of unit are related macular
Beovu brolucizumab-dbll 07-Oct-19 yes March 2020 degeneration
submitted January 2019, approved For the topical treatment of acne vulgaris in
Aklief trifarotene 04-Oct-19 yes November 2019 patients 9 years of age and older
submitted June 2019, approved April To treat irritable bowel syndrome with
Ibsrela tenapanor 12-Sep-19 yes 2020 constipation in adults.
To treat adult patients with Parkinson's disea
Nourianz istradefylline 27-Aug-19 no experiencing "off" episodes
Nourianz istradefylline 27-Aug-19 no experiencing "off" episodes
Nourianz istradefylline 27-Aug-19 no experiencing "off" episodes
Nourianz istradefylline 27-Aug-19 no experiencing "off" episodes OTAL: 102 HC/197 FDA
Nourianz istradefylline 27-Aug-19 no experiencing "off" episodes